Phreesia Reports $120.3M Q3 Revenue with $4.3M Net Income Recovery
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 08 2025
0mins
Source: Newsfilter
- Revenue Growth: Phreesia achieved total revenue of $120.3 million in Q3 2025, reflecting a 13% year-over-year increase, which underscores the company's strong performance in the healthcare services market and solidifies its market position.
- Client Expansion: The average number of healthcare services clients reached 4,520, up 7% year-over-year, indicating not only the market acceptance of the company's products but also laying a foundation for future revenue growth.
- Profitability Improvement: The company reported a net income of $4.3 million, a significant recovery from a net loss of $14.4 million in the same period last year, enhancing investor confidence in the company's financial health.
- Acquisition Strategy: Phreesia completed the acquisition of AccessOne for approximately $160 million, expected to contribute $7.5 million to future revenue and adjusted EBITDA, further driving the company's long-term growth strategy.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like PHR with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on PHR
Wall Street analysts forecast PHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHR is 29.09 USD with a low forecast of 24.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 14.660
Low
24.00
Averages
29.09
High
35.00
Current: 14.660
Low
24.00
Averages
29.09
High
35.00
About PHR
Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Barron’s Stock Selections Outperform the Market in 2025: Insights on Our Successes and Missteps.
Market Volatility: A little chaos in the market can create opportunities for stock-picking, allowing investors to identify undervalued stocks.
Investment Strategy: Embracing market fluctuations can lead to better investment decisions, as it encourages a more active approach to stock selection.
Continue Reading
Phreesia Shares Have Plummeted, But We Maintain Our Recommendation.
Stock Performance: Some stocks are performing well, while others are struggling, highlighting a mixed market environment.
Phreesia's Status: Phreesia is mentioned as a stock that does not fit neatly into the categories of hot or cold, suggesting a unique position in the market.
Continue Reading